查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
微量残存疾病 (MRD) 检验的全球市场 (2019-2029年):各检验类型、技术、用途、终端用户、地区的市场规模、占有率、趋势分析、机会、预测
市场调查报告书
商品编码
1274820

微量残存疾病 (MRD) 检验的全球市场 (2019-2029年):各检验类型、技术、用途、终端用户、地区的市场规模、占有率、趋势分析、机会、预测

Minimal Residual Disease Testing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Test Type ; By Technology ; By Application ; By End Use ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球微量残存疾病 (MRD) 检验的市场规模，从2022年的15亿4,000万美元，在预测期间中预计以14.6％的年复合成长率发展，2029年成长到39亿6,000万美元的规模。

全球微量残存疾病 (MRD) 检验的市场，由于精密医疗方法的高采用率，癌症的早期诊断、发现的趋势高涨，全球的癌症盛行率增加，正确可靠性高的诊断检验的需求剧增，呈现蓬勃发展。

本报告提供全球微量残存疾病 (MRD) 检验的市场调查，市场概要，市场成长的各种影响因素分析，技术趋势，法律制度，市场规模的变化、预测，各种区分、各地区/主要国家的明细，竞争环境，主要企业简介等彙整资讯。

目录

第1章 调查架构

第2章 摘要整理

第3章 全球微量残存疾病 (MRD) 检验市场相关洞察

  • 产业的价值链分析
  • DROC分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • 技术的进步/最近的开发
  • 法律规范
  • 波特的五力分析

第4章 全球微量残存疾病 (MRD) 检验市场:概要

  • 市场规模、预测
  • 市场占有率、预测
  • 各检验类型
    • DNA为基础的检验
    • RNA为基础的检验
    • 免疫学的检验
    • 其他
  • 各技术
    • NGS、PCR
    • 流式细胞技术
    • 萤光In-Situ杂合反应
    • 其他
  • 各用途
    • 骨髓恶性肿瘤
    • 固态肿瘤
    • 其他
  • 各终端用户
    • 医院
    • 专门诊所
    • 诊断实验室
    • 研究、学术机构
    • 其他
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东、非洲

第5章 北美的微量残存疾病 (MRD) 检验市场

  • 市场规模、预测
  • 市场占有率、预测
    • 各检验类型
    • 各技术
    • 各用途
    • 各终端用户
    • 各国

第6章 欧洲的微量残存疾病 (MRD) 检验市场

  • 市场规模、预测
  • 市场占有率、预测
    • 各检验类型
    • 各技术
    • 各用途
    • 各终端用户
    • 各国

第7章 亚太地区的微量残存疾病 (MRD) 检验市场

  • 市场规模、预测
  • 市场占有率、预测
    • 各检验类型
    • 各技术
    • 各用途
    • 各终端用户
    • 各国

第8章 南美的微量残存疾病 (MRD) 检验市场

  • 市场规模、预测
  • 市场占有率、预测
    • 各检验类型
    • 各技术
    • 各用途
    • 各终端用户
    • 各国

第9章 中东、非洲的微量残存疾病 (MRD) 检验市场

  • 市场规模、预测
  • 市场占有率、预测
    • 各检验类型
    • 各技术
    • 各用途
    • 各终端用户
    • 各国

第10章 竞争情形

  • 主要企业、产品清单
  • 市场占有率分析
  • 竞争基准:各经营参数
  • 主要的策略性展开 (M&A、联盟等)

第11章 COVID-19对全球微量残存疾病 (MRD) 检验市场的影响

第12章 企业简介 (企业概要、财务矩阵、竞争情形、主要人力资源、主要的竞争对手、联络处、策略性展望、SWOT分析)

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies
  • ARUP Laboratories
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Janssen Diagnostics LLC
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • QIAGEN N.V.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
  • 其他的主要企业

第13章 主要策略性建议

第14章 调查手法

简介目录
Product Code: BWC23357

Global Minimal Residual Disease Testing Market Size More Than Doubles to Reach USD 4 Billion by 2029.

Global minimal residual disease testing market is flourishing because of high adoption of precision medicine approaches, growing trend towards early cancer diagnosis and detection, and increasing prevalence of cancer worldwide, leading to surging demand for accurate and reliable diagnostic tests.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global minimal residual disease testing market size at USD 1.54 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global minimal residual disease testing market size to grow at a significant CAGR of 14.6% reaching a value of USD 3.96 billion by 2029. Major growth drivers for global minimal residual disease testing market include growing cancer patient population, awareness among consumers of the importance of therapy, as well as increased investments in research, and high disposable income in developing nations. A primary growth driver of the market growth is the escalating prevalence of cancer. According to the World Health Organization, cancer is currently the second most common cause of death worldwide. In 2020, there were 19.3 million reported cases of cancer and 9.96 million deaths related to the disease. The International Agency for Research on Cancer predicts that the number of cancer cases will rise to 21.9 million by 2025 and 24.6 million by 2030. As a result, governments are expected to establish new cancer screening programs to address this surge in cases. Also, the market is expected to experience growth due to increased investments in MRD (minimal residual disease) testing programs. MRD diagnostic and monitoring research is expanding, which is creating demand for these services. However, limited availability of skilled healthcare professionals to perform and interpret MRD tests and concerns over the accuracy and reliability of MRD tests are anticipated to restrain the overall market growth.

Global Minimal Residual Disease Testing Market - Overview:

Global minimal residual disease (MRD) testing market refers to the market for diagnostic tests used to detect the presence of cancer cells in patients who have undergone treatment. MRD testing is a highly sensitive and specific technique that is capable of detecting small amounts of cancer cells that may remain in a patient's body after treatment. The MRD testing market includes products and services such as assays, flow cytometers, and other testing equipment, as well as related services like sample preparation and analysis. The market caters to healthcare providers, research organizations, and pharmaceutical companies who use MRD testing for disease monitoring, treatment selection, and clinical trial endpoints.

Impact of COVID-19 on Global Minimal Residual Disease Testing Market

COVID-19 had a detrimental impact on the global minimal residual disease (MRD) testing market. With the focus on the virus and the strain on healthcare systems, the demand for MRD testing was affected. The restrictions imposed due to the pandemic, such as social distancing and lockdown measures, have also resulted in delays or cancellations of elective procedures, including MRD testing. Also, the disruption in the supply chain and manufacturing processes has led to a shortage of necessary components and instruments required for testing. The uncertain economic conditions and reduced funding for research and development may further impede the growth of the MRD testing market in the near future.

Global Minimal Residual Disease Testing Market - By Test Type

Based on test type, the global minimal residual disease testing market is divided into DNA-Based Test, RNA-Based Test, and Immunological Test segments. The DNA-based tests segment held the highest share of the MRD testing market due to their high sensitivity and specificity in detecting cancer cells. However, the RNA-based tests segment is expected to grow at the highest CAGR during the forecast period due to advancements in technologies like next-generation sequencing (NGS) and digital PCR.

Competitive Landscape:

Major players operating in the global minimal residual disease testing market include: Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, ARUP Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Illumina, Inc., Invivoscribe, Inc., Janssen Diagnostics LLC, Luminex Corporation, Myriad Genetics, Inc., Natera, Inc., QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Minimal Residual Disease Testing Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Minimal Residual Disease Testing Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Minimal Residual Disease Testing Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Growing prevalence of cancer worldwide, leading to increased demand for accurate and reliable diagnostic tests
      • 3.2.1.2. Increasing adoption of precision medicine approaches
      • 3.2.1.3. Growing trend towards early cancer diagnosis and detection
    • 3.2.2. Restraints
      • 3.2.2.1. Limited availability of skilled healthcare professionals to perform and interpret MRD tests
      • 3.2.2.2. Concerns over the accuracy and reliability of MRD tests
    • 3.2.3. Opportunities
      • 3.2.3.1. Increasing adoption of advanced technologies, such as next-generation sequencing
      • 3.2.3.2. Growing trend towards personalized cancer care, which requires accurate and reliable measurement
    • 3.2.4. Challenges
      • 3.2.4.1. Need for continuous investment in research and development to stay competitive
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Minimal Residual Disease Testing Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Test Type
      • 4.2.1.1. DNA-Based Test
      • 4.2.1.2. RNA-Based Test
      • 4.2.1.3. Immunological Test
      • 4.2.1.4. Others
    • 4.2.2. By Technology
      • 4.2.2.1. NGS, PCR
      • 4.2.2.2. Flow Cytometry
      • 4.2.2.3. Fluorescence In-Situ Hybridization
      • 4.2.2.4. Others
    • 4.2.3. By Application
      • 4.2.3.1. Hematological Malignancies
      • 4.2.3.2. Solid Tumors
      • 4.2.3.3. Others
    • 4.2.4. By End Use
      • 4.2.4.1. Hospitals
      • 4.2.4.2. Specialty Clinics
      • 4.2.4.3. Diagnostic Laboratories
      • 4.2.4.4. Research and Academic Institutes
      • 4.2.4.5. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America (LATAM)
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Minimal Residual Disease Testing Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type
    • 5.2.2. By Technology
    • 5.2.3. By Application
    • 5.2.4. By End Use
    • 5.2.5. By Country
      • 5.2.5.1. United States
      • 5.2.5.1.1. By Test Type
      • 5.2.5.1.2. By Technology
      • 5.2.5.1.3. By Application
      • 5.2.5.1.4. By End Use
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Test Type
      • 5.2.5.2.2. By Technology
      • 5.2.5.2.3. By Application
      • 5.2.5.2.4. By End Use

6. Europe Minimal Residual Disease Testing Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End Use
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Test Type
      • 6.2.5.1.2. By Technology
      • 6.2.5.1.3. By Application
      • 6.2.5.1.4. By End Use
      • 6.2.5.2. United Kingdom
      • 6.2.5.2.1. By Test Type
      • 6.2.5.2.2. By Technology
      • 6.2.5.2.3. By Application
      • 6.2.5.2.4. By End Use
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Test Type
      • 6.2.5.3.2. By Technology
      • 6.2.5.3.3. By Application
      • 6.2.5.3.4. By End Use
      • 6.2.5.4. France
      • 6.2.5.4.1. By Test Type
      • 6.2.5.4.2. By Technology
      • 6.2.5.4.3. By Application
      • 6.2.5.4.4. By End Use
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Test Type
      • 6.2.5.5.2. By Technology
      • 6.2.5.5.3. By Application
      • 6.2.5.5.4. By End Use
      • 6.2.5.6. Belgium
      • 6.2.5.6.1. By Test Type
      • 6.2.5.6.2. By Technology
      • 6.2.5.6.3. By Application
      • 6.2.5.6.4. By End Use
      • 6.2.5.7. Russia
      • 6.2.5.7.1. By Test Type
      • 6.2.5.7.2. By Technology
      • 6.2.5.7.3. By Application
      • 6.2.5.7.4. By End Use
      • 6.2.5.8. The Netherlands
      • 6.2.5.8.1. By Test Type
      • 6.2.5.8.2. By Technology
      • 6.2.5.8.3. By Application
      • 6.2.5.8.4. By End Use
      • 6.2.5.9. Rest of Europe
      • 6.2.5.9.1. By Test Type
      • 6.2.5.9.2. By Technology
      • 6.2.5.9.3. By Application
      • 6.2.5.9.4. By End Use

7. Asia-Pacific Minimal Residual Disease Testing Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End Use
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Test Type
      • 7.2.5.1.2. By Technology
      • 7.2.5.1.3. By Application
      • 7.2.5.1.4. By End Use
      • 7.2.5.2. India
      • 7.2.5.2.1. By Test Type
      • 7.2.5.2.2. By Technology
      • 7.2.5.2.3. By Application
      • 7.2.5.2.4. By End Use
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Test Type
      • 7.2.5.3.2. By Technology
      • 7.2.5.3.3. By Application
      • 7.2.5.3.4. By End Use
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Test Type
      • 7.2.5.4.2. By Technology
      • 7.2.5.4.3. By Application
      • 7.2.5.4.4. By End Use
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Test Type
      • 7.2.5.5.2. By Technology
      • 7.2.5.5.3. By Application
      • 7.2.5.5.4. By End Use
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Test Type
      • 7.2.5.6.2. By Technology
      • 7.2.5.6.3. By Application
      • 7.2.5.6.4. By End Use
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Test Type
      • 7.2.5.7.2. By Technology
      • 7.2.5.7.3. By Application
      • 7.2.5.7.4. By End Use
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Test Type
      • 7.2.5.8.2. By Technology
      • 7.2.5.8.3. By Application
      • 7.2.5.8.4. By End Use
      • 7.2.5.9. Vietnam
      • 7.2.5.9.1. By Test Type
      • 7.2.5.9.2. By Technology
      • 7.2.5.9.3. By Application
      • 7.2.5.9.4. By End Use
      • 7.2.5.10. Rest of APAC
      • 7.2.5.10.1. By Test Type
      • 7.2.5.10.2. By Technology
      • 7.2.5.10.3. By Application
      • 7.2.5.10.4. By End Use

8. Latin America Minimal Residual Disease Testing Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End Use
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Test Type
      • 8.2.5.1.2. By Technology
      • 8.2.5.1.3. By Application
      • 8.2.5.1.4. By End Use
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Test Type
      • 8.2.5.2.2. By Technology
      • 8.2.5.2.3. By Application
      • 8.2.5.2.4. By End Use
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Test Type
      • 8.2.5.3.2. By Technology
      • 8.2.5.3.3. By Application
      • 8.2.5.3.4. By End Use
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Test Type
      • 8.2.5.4.2. By Technology
      • 8.2.5.4.3. By Application
      • 8.2.5.4.4. By End Use
      • 8.2.5.5. Rest of LATAM
      • 8.2.5.5.1. By Test Type
      • 8.2.5.5.2. By Technology
      • 8.2.5.5.3. By Application
      • 8.2.5.5.4. By End Use

9. Middle East & Africa Minimal Residual Disease Testing Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End Use
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Test Type
      • 9.2.5.1.2. By Technology
      • 9.2.5.1.3. By Application
      • 9.2.5.1.4. By End Use
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Test Type
      • 9.2.5.2.2. By Technology
      • 9.2.5.2.3. By Application
      • 9.2.5.2.4. By End Use
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Test Type
      • 9.2.5.3.2. By Technology
      • 9.2.5.3.3. By Application
      • 9.2.5.3.4. By End Use
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Test Type
      • 9.2.5.4.2. By Technology
      • 9.2.5.4.3. By Application
      • 9.2.5.4.4. By End Use
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Test Type
      • 9.2.5.5.2. By Technology
      • 9.2.5.5.3. By Application
      • 9.2.5.5.4. By End Use
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Test Type
      • 9.2.5.6.2. By Technology
      • 9.2.5.6.3. By Application
      • 9.2.5.6.4. By End Use
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Test Type
      • 9.2.5.7.2. By Technology
      • 9.2.5.7.3. By Application
      • 9.2.5.7.4. By End Use
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Test Type
      • 9.2.5.8.2. By Technology
      • 9.2.5.8.3. By Application
      • 9.2.5.8.4. By End Use

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Minimal Residual Disease Testing Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Minimal Residual Disease Testing Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Abbott Laboratories
  • 12.2. Adaptive Biotechnologies
  • 12.3. Agilent Technologies
  • 12.4. ARUP Laboratories
  • 12.5. Bio-Rad Laboratories
  • 12.6. F. Hoffmann-La Roche AG
  • 12.7. Illumina, Inc.
  • 12.8. Invivoscribe, Inc.
  • 12.9. Janssen Diagnostics LLC
  • 12.10. Luminex Corporation
  • 12.11. Myriad Genetics, Inc.
  • 12.12. Natera, Inc.
  • 12.13. QIAGEN N.V.
  • 12.14. Sysmex Corporation
  • 12.15. Thermo Fisher Scientific, Inc.
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations